Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

| More on:
Medicinal research is conducted on cannabis.

Source: Getty Images

Cannabis stocks had yet another terrible year in 2022. That was quite evident. The industry has grappled with serious structural challenges with no near-term solution. US legalization could bring a big respite for the sector as the move will open significant growth opportunities. However, the industry has been unlucky on that front so far.

Why TLRY stock halved last year

One of the biggest pot stocks, Tilray (TSX:TLRY) lost 50% of its value in the last 12 months, in line with its peers. And not just last year. Cannabis stocks have been losing value for the last several years. Poor financial growth amid saturated markets has been a key concern even for established players.  

Tilray is a $2.4 billion cannabis-lifestyle and consumer packaged goods company that operates in Canada, the US, Europe, Latin America, and Australia. The cannabis industry in Europe offers huge growth prospects as countries there are at various stages of legalization. 

Tilray operates within four key verticals, the first being the cannabis segment, which contributes 43% to its revenues. It takes care of the cultivation and production of both adult-use and medical-use cannabis. The Distribution segment deals with the purchase and resale of pharmaceutical and wellness products.

The Beverage alcohol business – operating the production, sales and marketing of the alcohol business –brought in 11% of the total sales in 2022. The Wellness business deals with hemp-based food and other wellness products and contributes 9% to the total revenues.

The alcohol beverage segment has seen some strong growth in the last few years and will likely be the major growth driver.

Financial growth and growth prospects

Tilray reported total revenues of $628 million for the fiscal year that ended on May 2022. That was a decent 26% increase compared to the previous year. On the contrary, many pot companies have seen declining topline growth in the last few years.

On the bottom-line front, Tilray continues to remain a loss-making venture. For the fiscal year that ended in May 2022, it reported a $477 million net loss, expanding from $367 million in the previous fiscal year. It has $490.6 million in cash and cash equivalents as of August 2022 and looks well capitalized.

However, Tilray looks well placed for the future compared to its peers. It caters to geographically diversified areas with its differentiated product base, which gives it an important edge over other established companies.

Cannabis stock rebound

Cannabis investors have been burned badly in the last few years due to massive drawdowns. Notably, TLRY shares are currently trading close to four times sales and do not look too expensive. However, despite the steep correction, we might not see an immediate recovery in cannabis stocks. That’s because of their unending challenges.

TLRY stock could outperform in the long term, but it remains a risky bet. Its large price swings amid financial and regulatory uncertainty might keep conservative investors at bay. But if you have the stomach for its high volatility, you might reap outsized gains in the years to come.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Fool contributor Vineet Kulkarni has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

The Single Best Pot Stock to Buy in December 2022

Canopy Growth Corp. (TSX:WEED) is still my favourite pot stock to snatch up in the final days of December 2022.

Read more »